Related Experiment Video
Updated: Dec 7, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
[Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement]
1Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Insights
Large B-cell lymphoma (LBCL) with IRF4 rearrangement presents distinct clinicopathological features. Further studies are needed to determine the relationship between clinical stage and prognosis in these cases.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Large B-cell lymphoma (LBCL) is a heterogeneous group of lymphoid malignancies.
- The role of IRF4 rearrangement in LBCL pathogenesis and its clinicopathological significance require further elucidation.
Purpose of the Study:
- To investigate the clinicopathological characteristics of LBCL associated with IRF4 gene rearrangement.
- To analyze the morphological, immunophenotypic, and genetic features of these specific LBCL cases.
Main Methods:
- Retrospective analysis of seven LBCL cases with IRF4 rearrangement.
- Evaluation using hematoxylin and eosin staining, immunohistochemistry, and fluorescence in situ hybridization.
- Review of relevant scientific literature.
Main Results:
- Cases presented with diverse locations (tonsils, lymph nodes, adenoid) and varied histological patterns (follicular, diffuse).
- Tumor cells showed medium to large size with centroblastic or blastoid morphology; high Ki-67 index (>80%) was observed in all cases.
- IRF4 gene rearrangement was consistently detected, with bcl-6 rearrangement in two cases; immunophenotype included CD20, PAX-5, bcl-6, and MUM1 positivity.
Conclusions:
- LBCL with IRF4 rearrangement represents a distinct clinicopathological entity.
- These findings suggest a broader spectrum of morphological and behavioral patterns in IRF4-rearranged LBCL.
- Prospective studies with larger cohorts are necessary to establish the prognostic implications of clinical stage.
Abstract:
Objective: To study the clinicopathological features of large B-cell lymphoma (LBCL) with IRF4 rearrangement. Methods: Seven cases of LBCL with IRF4 rearrangement collected at the First Affiliated Hospital of Nanjing Medical University from November 2018 to October 2019 were evaluated by hematoxylin and eosin staining, immunohistochemistry and fluorescence in situ hybridization detection. The relevant literature was reviewed. Results: Four tumors were located in the tonsils, 2 tumors in the lymphoid nodes and one tumor in the adenoid.The patients were 3 males and 4 females patients with a median age of 24 years (range, 6 to 39 years).Microscopically, entirely follicular pattern was present in one case, entirely diffuse pattern in 2 cases, and follicular and diffuse pattern in other 4 cases. The tumor cells were medium to large in size and showed the morphology of centroblasts or blastoid cells with irregular nuclei, brisk mitotic activity in 3 cases and starry sky in 2 cases. All of the cases were positive for CD20, PAX-5, bcl-6, and MUM1 and had a Ki-67 index>80%, while CD10 and bcl-2 were positive in 3 cases. IRF4 gene rearrangement was identified in all cases and bcl-6 gene rearrangement in 2 cases. All patients presented with localized disease with clinical stage Ⅰ or Ⅱ, except one with stage Ⅳ at presentation and a new lesion in the mediastinum developed 8 months later. Conclusions: LBCL with IRF4 rearrangement is a clinicopathologically distinct entity. The observations reveal a broader spectrum of morphology and biological behaviors. The relationship between clinical stage and prognosis needs to be determined in more cases.
More Related Videos
07:52Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
07:39Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019